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(Riordan et al, 1989). CFTR, a PKA‐activated Cl channel, is a
rate‐limiting factor for ﬂuid absorption in numerous epithelia,
such as the lung, pancreas, intestine and sweat glands (Robert
et al, 2008). CFTR regulates different ion transports, including
Cl/HCO3
 secretion, by interacting with SLC26An transporters
(Ko et al, 2004; Rode et al, 2012), and Naþ absorption, possibly
by interacting with the epithelial sodium channel ENaC (Berdiev
et al, 2009).
The CFTR‐coded 1480‐amino acid protein, which shares
structural and folding features with members of the ATP‐
binding cassette (ABC) transporters, consists of two nucleotide
binding domains (NBDs), two transmembrane domains
(TMDs) and one mostly unstructured regulatory domain
(RD). The latter is speciﬁc for CFTR and its functions (Ollero
et al, 2006).
DF508‐CFTR has a reduced ability to escape from the
endoplasmic reticulum (ER) and undergoes premature degrada-
tion in a proteasome‐dependentmanner (Jensen et al, 1995;Ward
et al, 1995; Younger et al, 2006). Thus, a signiﬁcant decrease in
functional CFTR expression occurs at the apical plasma
membrane, which has been deﬁned as a result of a trafﬁcking
or folding defect (Carlile et al, 2007).Moreover, a residual amount
of DF508‐CFTR, which in some conditions reaches its native
destination, exhibits a dysfunction associated with lower activity,
termed a gating defect (Dalemans et al, 1991).
Since the discovery of mutations in CFTR as the cause of
CF, a number of studies have been conducted to ﬁnd a
pharmacological approach to correct the dysfunction of the
mutated proteins (Becq et al, 2011). For missense mutations,
such as DF508‐CFTR, small molecules (correctors) need to
facilitate trafﬁcking and delivery of the abnormal protein to
the plasma membrane and/or to improve its channel gating
(potentiators) (Riordan, 2008). A successful example of
potentiator is a VX‐770/Ivacaftor, which ameliorates signiﬁ-
cantly the clinical status of CF patients bearing the G551D
mutation and shows no major side effects (Ramsey et al, 2011;
Yu et al, 2012).
On the other hand, the fact that protein folding and trafﬁcking
are complex, multistep processes involving multiple cellular
targets signiﬁcantly complicates the task of development of
DF508‐CFTR correctors (Kalid et al, 2010; Pedemonte
et al, 2005b). Indeed, such molecules are decisively in the
minority among the known CFTR modulators.
The hypothesis driven approach has led to the discovery of
small molecules, such as phosphodiesterase‐type 5 (PDE5)
inhibitors (Dormer et al, 2005) (e.g. sildenaﬁl), alpha‐glucosi-
dase inhibitors (Norez et al, 2006) (e.g. miglustat) and histone
deacetylase‐7 inhibitors (Hutt et al, 2010) (e.g. SAHA), that
interact with proteins responsible for DF508‐CFTR processing
and increase the amount of DF508‐CFTR at the plasma
membrane. Other molecules such as curcumin or resveratrol
derived from plants may act by modifying keratin 18 (K18)
network (Hamdaoui et al, 2011; Lipecka et al, 2006). K18
heterodimerizes with keratin 8 (K8) and further evidence
suggests that both proteins play a role in the trafﬁcking of CFTR/
DF508‐CFTR (Colas et al, 2012; Duan et al, 2012). Accordingly,EMBO Mol Med (2013) 5, 1484–1501 we have reported that a decrease in K8 expression leads to
functional correction of DF508‐CFTR (Colas et al, 2012).
Discovery of the high‐throughput screening approach has
resulted in a signiﬁcant increase in the number of compounds
found to be able to correct the DF508‐CFTR trafﬁcking defect.
Among them are many distinct chemical classes like amino-
arylthiazoles, quinazolinylaminopyrimidinones, bisaminome-
thylbithiazoles (e.g. Corr‐4a) (Pedemonte et al, 2005b), 1,4‐
dihydropiridines (Pedemonte et al, 2005a), quinazolines (e.g.
VRT‐325) (Loo et al, 2005), the sildenaﬁl analogues like
KM11060 (Robert et al, 2008) or galfenine (Robert
et al, 2010), and up to date the most potent corrector VX‐809
(Van Goor et al, 2011). The mechanism of action for these
compounds is not precisely known, which dramatically
decreases the chance for further rational development.
A commonly accepted hypothesis postulates that some
correctors (e.g. VRT‐325, MPB, Corr‐4a and the dual activity
molecule VRT‐532) interact directly with DF508‐CFTR by
stabilising its structure, to promote folding as pharmacological
chaperones (Loo et al, 2005; Pedemonte et al, 2005b; Sampson
et al, 2011; Wellhauser et al, 2009). Based on this presumption,
Kalid et al (2010) used an approach based on the virtual
screening (VS) method (omitting the dynamic behaviour of the
protein) to identify new modulators of DF508‐CFTR. In this
study, three interdomain cavities on a full‐length model of
DF508‐CFTR were used as receptors for molecular docking.
Selected molecules were tested at the functional level in various
cell types and found to behave either as potentiators or
correctors, or even display dual activity. Unfortunately, these
molecules were not active in human bronchial epithelial
(HBE) cells (Kalid et al, 2010) nor they were tested in CF
animal models.
Among the different mechanisms responsible for correcting/
potentiating activity, the structural stabilization by binding of
small molecules to DF508‐NBD1 has also been tested. Sampson
et al (2011) reported that the corrector VRT‐325 and dual
activity compound VRT‐532 may directly interact with DF508‐
NBD1 and thermally stabilize the protein. A similar observation
was made for the RDR1 molecule, which was tested together
with 220 correctors previously identiﬁed using a cell‐based
assay (Carlile et al, 2007). Recent ﬁndings shown also that
VRT‐325 exhibits undesirable effect and inhibits the ATPase
activity of DF508‐CFTR by decreasing its afﬁnity for ATP (Kim
et al, 2010).
A study by Wieczorek & Zielenkiewicz (2008) revealed the
differences in dynamic behaviour between DF508‐NBD1 and
wild type NBD1 (WT‐NBD1). Indeed, the NBD1 domain of
DF508‐CFTR exhibits broader conformational freedom than
WT‐NBD1, which is probably induced by reorganization of the
interactions network between residues. Such unique behaviour
of mutated NBD1 contributes to the exposure of more
hydrophobic regions, which in turn might induce interaction
with housekeeping proteins.
On the basis of MD results we suggested in the present work
an entirely new mechanism of pharmacological intervention to
overcome the dysregulated trafﬁcking of DF508‐CFTR. We
hypothesized that identiﬁed small molecules that target the2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1485
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1486unique conformation ofDF508‐NBD1may prevent its interaction
with protein(s) recognising the mutant as improperly folded
and lead to its expression at the plasma membrane. According
to this assumption we performed structure‐based virtual
screening protocol, thus resulted in identiﬁcation of four new
effective correctors of DF508‐CFTR trafﬁcking; at least two of
them might disrupt the interaction between DF508‐CFTR and
keratin 8 (K8).RESULTS
Virtual screening strategy
We have previously shown that the DF508 mutation increases
the ﬂexibility of NBD1 and, as a consequence, the DF508‐NBD1
mutant displays a much larger average solvent‐accessible
surface, which is comprised of hydrophobic residues, than the
WT protein (Wieczorek & Zielenkiewicz, 2008). As hypothe-
sized, abnormally large hydrophobic areas on the DF508‐CFTR
protein surface might embody the sites of interaction with
housekeeping proteins, leading to premature degradation. In
addition, a fraction of DF508‐NBD1 dynamic trajectory occupies
a conformational space unavailable in the WT protein and
possesses cavities on the surface, often deﬁned in the literature
as ‘druggable’ sites (Nayal & Honig, 2006).
We assumed that binding of small molecules onto these
hydrophobic areas could prevent pharmacologically an
unwanted situation, protecting DF508‐CFTR from premature
degradation. To address this question, we used a structure‐
based VS approach to discover chemical compounds with
favourable binding characteristics to the DF508‐NBD1 protein
surface.
According to a previous study, the atomic coordinates of the
DF508‐NBD1 frame that is most distinct from WT‐NBD1 were
adopted as a starting point for molecular docking (MD)
(Wieczorek & Zielenkiewicz, 2008). Two wide cavities – pockets
1 and 2 (Supporting Information Fig S1 and Supporting
Information Materials and Methods Section) – were then
identiﬁed around the exposed hydrophobic surface of the
DF508 domain and treated as two independent receptors for VS.
We decided to screen the National Cancer Institute diversity
set I (NCIDS), a relatively modest database consisting of 1990
non‐redundant, diverse chemical structures. Molecules were
selected according to their unique scaffold as a representative
set for over 140,000 available structures from the full NCI
database. The NCIDS enabled us to test more extensively the
conformational space of the ligands inside the binding pocket in
a reasonable amount of time. Each member of the chemical
library was docked into potential binding sites using the DOCK
program (Moustakas et al, 2006). Commonly used docking
algorithms are able to predict the binding conformation of
docked ligands inside a receptor with acceptable accuracy;
however, though rarely, scoring functions can identify the
optimal conformation (Leach et al, 2006). Therefore, we
extended the output to the 50 best conformers per molecule
(according to internal scoring function) and evaluated them
further outside the DOCK program. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.In a ﬁrst step we performed minimization of all selected
conformers in rigid surrounding protein using MMFF94 force
ﬁeld. Subsequently, all potential complexes were assessed
primarily by value of electrostatic and steric energy contribution
calculated by a ‘dock module’ implemented in Sybyl program,
and then by various scoring functions selected from the main
classes: knowledge‐based, molecular force ﬁeld‐based and
empirical scoring functions (Leach et al, 2006). On the basis
of results from each scoring function, the three best conforma-
tions per molecule were saved and subjected to full ligand–
receptor minimization and then rescored again, using the
selected functions. Finally, instead of using consensus scoring
protocols, which have questionable efﬁciency (Englebienne &
Moitessier, 2009), we focused our attention on the top 10
molecules for each scoring function.
After a visual assessment, we identiﬁed 12 candidate
compounds that were obtained from the NCI as test samples
and further evaluated them by biological assays; they were
NSC37173, NSC11668, NSC130813, NSC9608, NSC140873,
NSC118208, NSC73100, NSC299589, NSC11237, NSC123526,
NSC105687 and NSC407882 (Supporting Information Tables S1
and S2).
To test our hypothesis postulating that compounds selected
by in silico analysis can correct DF508‐CFTR function, we
evaluated the effects of these compounds on several DF508‐
CFTR parameters: protein processing and channel function in
three cell lines (HeLa, CF‐KM4) and on human bronchial
primary epithelial cells from CF patients (CF‐HBE) as well as
in vivo analysis of nasal potential difference in DF508/DF508
mice.
Rescue ofDF508 chloride channel activity by the drugs in HeLa
transfected cells
To test the effects of drugs on DF508‐CFTR trafﬁcking and
function, we ﬁrst evaluated I permeability using a robotic, cell‐
based macroscopic assay. DF508‐CFTR‐expressing HeLa cells
were treated for 24 h with 1mM candidate correctors and CFTR‐
dependent radiolabelled iodide (I) efﬂux was measured after
stimulation of cells with 10mM forskolin (Fsk) and 30mM
genistein (Gst). Assuming that maximal correcting effect is
obtained after incubation of cells at 27°C (Denning et al, 1992),
the efﬁciency of correctors was evaluated by comparing I ﬂuxes
with those obtained at 27°C. The efﬁciency was also compared
to that of two reference correctors, Corr‐4a and VX‐809.
Treatments with compounds 130813 and 118208, which target
pocket 1, and 73100 and 407882, which target pocket 2 (Fig 1 and
Supporting Information Table S1), led to a signiﬁcant increase in
cAMP‐stimulated I efﬂux (Fig 2A and B), with the most potent
molecule being 407882. At this low dose (1mM), 407882was less
potent than correction at 27°C but twofold more efﬁcient that
10mMCorr‐4a and comparable to 10mMVX‐809. Examples of I
efﬂux stimulation after treatment with each of the four active
compounds are illustrated in Fig 2A. cAMP‐stimulated I efﬂux
was completely inhibited when experiments were performed in
the presence of the CFTR channel blocker CFTRinh‐172.
We further tested the effects of the four compounds on
I efﬂux using a wide range of concentrations, and determinedEMBO Mol Med (2013) 5, 1484–1501
Figure 1. Binding modes for active correctors identiﬁed by VS. Potential hydrogen bonds are represented by black dashed lines. Distances in Angstroms (A˚) are
also listed. Essential residues are labelled.
A. Compounds 130813 and 118208 were predicted to bind to pocket 1.
B. The molecules 407882 and 73100 should bind to pocket 2 and such residues as Phe490, Ser492, Arg560 and Lys564 are essential for the formation of a polar
interaction with both ligands.
Research Articlewww.embomolmed.org
Norbert Odolczyk et al.the EC50 for compound 130813, which targets pocket 1, and
compounds 407882 and 73100, which target pocket 2, at 1mM
(with 95% conﬁdence interval from 2.1 to 4.9mM), 7.7mM (with
95% conﬁdence interval from 5.4 to 1.1mM) and 844 nM (with
95% conﬁdence interval from 0.6 to 1.2mM), respectively
(Fig 2C). Of note, EC50 of VX‐809 was reported to be 0.5mM (Van
Goor et al, 2011). On the contrary, the EC50 for 118208, which
targets pocket 1, was not determined precisely because the
maximum I efﬂux was not reached, even at 100mM (data not
shown). Inspection of this incomplete concentration–responseEMBO Mol Med (2013) 5, 1484–1501 curve for 118208 suggests an EC50> 100mM, a value far above
those calculated for compounds 130813, 407882 and 73100.
The efﬁcacy of the four compounds as correctors for F508‐
CFTR trafﬁcking was further evaluated by immunoblot analysis.
We assumed that detection of a fully glycosylated protein band
(band C of about 170 kDa, mature protein) suggested correct
processing of DF508‐CFTR (Cheng et al, 1991). A representative
immunoblot is shown in Fig 2D, upper panel. Anti‐CFTR
antibodies detect two bands in WT‐CFTR cell lysate (WT lane in
Fig 2D, upper panel). The diffuse band of approximately 170 kDa2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1487
Figure 2. Effect of compounds on iodide efﬂux and CFTR maturation in DF508‐CFTR‐expressing HeLa cells.
A. Representative I efflux curves obtained in HeLa cells stably transfected withDF508-CFTR after treatment for 24 hwith 1mMof the indicated compounds. The
CFTR-dependent response was induced by co-treatment with 10mM forskolin (Fsk) and 30mM genistein (Gst), as indicated by the horizontal bar above each
trace; CFTR-dependent flux was identified by the use of the CFTR inhibitor CFTRinh-172 (10mM).
B. Histogram showing the peak amplitude of Fsk/Gst-dependent I effluxes in cells treated with the indicated drugs, as shown in A. The values represent the
meanþ SEM of three independent experiments; p¼0.04, p¼0.01 for 118208, p¼0.0002 for 130813, p¼0.005 for Corr-4a; p¼0.01 for 407882,
p¼0.0005 for VX-809, p¼0.0001 for 27˚C; Statistics: One-way Anova test followed by Bonferroni post hoc test.
C. EC50 for active compounds targeting pocket 2 (407882 and 73100) and pocket 1 (130813). For 118208, EC50 could not be precisely determined because the
maximum of I efflux was not reached, even at 100mM (also shown).
D. Effects of the indicated compounds on CFTR processing. Upper panel: representative immunoblots of WT-CFTR and DF508-CFTR from HeLa cells treated with
1mM of the indicated compounds for 24 h in the presence of anti-CFTR monoclonal antibody 24-1. The positions of mature (band C) and immature (band B)
CFTR are indicated. Note that WT-CFTR and DF508-CFTR are from parallel experiments. Lower panel: relative abundance of mature CFTR, expressed as the
ratio of band C to bands (CþB). NT, untreated cells. The values represent the meanþ SEM of seven independent experiments; p¼0.005. Statistics: unpaired
Student’s t-test.
Research Article www.embomolmed.org
Discovery of Novel DF508‐CFTR Correctors
1488  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1484–1501
Figure 3. Synergistic effects of active compounds
on iodide efﬂux in DF508‐CFTR‐expressing HeLa
cells. The CFTR-dependent response was induced by
co-treatment with 10mM Fsk and 30mM Gst.
A. Histogram of I efflux for cells treated for 24 h
with 118208 and 407882; values represent the
meanþ SEM of four independent experiments;
p¼0.0007 for 0.1mM, p¼0.0001 for 1mM as
compared to the amplitudes of individual
compounds.
B. Histogram of I efflux for cells treated for 24 h
with 118208 and 73100; values represent the
meanþ SEM of four independent experiments;
p¼0.0008 for 0.1mM, p¼0.0006 for 1mM,
p¼0.0001 for 100mM. Statistics: One-way Anova
test followed by Bonferroni post hoc test.
Research Articlewww.embomolmed.org
Norbert Odolczyk et al.corresponds to band C. A second band at about 145 kDa (band B)
corresponds to an immature core‐glycosylated protein located in
the ER. In DF508‐CFTR‐expressing cells, only the immature
protein was detectable (DF508 NT lane in Fig 2D, upper panel).
Band C was clearly detectable in cells treated with 1mM 407882
compared to untreated cells, whereas the signal at 170 kDa in
lysate from cells treated with 1mM 118208 or 130813 was not
signiﬁcantly different from that of the untreated cells. In
addition, C band intensity was very slightly increased in cells
treated with 1mM 73100. The relative abundance of mature
CFTR, expressed as the ratio of band C to bands CþB, is shown
in Fig 2D, lower panel. Only compound 407882 signiﬁcantly
increased the relative abundance of mature CFTR, in agreement
with its most potent activity to increase cAMP‐stimulated
I efﬂux.
To test whether the compounds exhibit potentiator activity
independent of their effect on CFTR trafﬁcking, we examined I
efﬂux in untreated WT‐CFTR HeLa cells (Supporting Informa-
tion Fig S2). Compounds were added along with Fsk, and their
effects were compared to that of Fsk alone or Fsk plus Gst
(Wellhauser et al, 2009). Unlike Gst, each molecule added with
Fsk induced an I efﬂux similar to that of forskolin alone,
demonstrating that the candidate compounds are not potentia-
tors of WT‐CFTR activity.EMBO Mol Med (2013) 5, 1484–1501 If two compounds are able to correct DF508‐CFTR function by
binding to the same protein conformation but at different surface
cavities, their effects could be either additive or synergistic. To
test for these effects, cells were treated for 24 h with three
concentrations of either 407882 or 73100 together with 1mM
118208. The I permeability tests (Fig 3) showed that combined
treatment with either compound with 118208 results in a more
than additive efﬂux, consistent with a synergistic effect. Of note,
the maximal activity that could be measured was achieved when
1mM 118208 was combined with 0.1mM 407882 or 1mM 73100.
The activity of each compound was also evaluated using
patch‐clamp experiments. CFTR‐related current density (IDF508‐
CFTR; pA/pF) is deﬁned as cAMP‐stimulated current minus the
current recorded after inhibition with 5mM CFTRinh‐172. This
value is then normalized to cell capacitance. Examples of current
traces recorded for one compound (118208) at different voltages
from 100 to þ80mV, before and after stimulation with CPT‐
cAMP/IBMX, and in the presence of CFTRinh‐172 are illustrated
in Fig 4A. I/V curves representing mean IDF508‐CFTR for cells
treated by compounds 118208, 407882 and 118208þ 407882 are
shown in Fig 4B. Fig 4C summarizes the mean current
amplitudes recorded at 60mV under different experimental
conditions. Treatment for 24 h at low temperature (27°C) or with
10mM Corr‐4A and 10mM VX‐809 served as positive controls,2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1489
Figure 4. Effect of compounds on whole cell Cl
currents recorded in HeLa cells by patch‐clamp
experiments.
A. Representative current traces recorded by
holding the membrane potential at 0mV and
pulsing the voltages in the range 100 to
þ80mV at 20mV steps for a cell treated for 24 h
by compound 118208. Current traces recorded:
at the basal level (upper panel); in the presence
of CPT-cAMP/IBMX (middle panel); in the
presence of CPT-cAMP/IBMXþCFTRinh-172
(lower panel).
B. Mean CFTR-related current/voltage relationships
illustrated for cells treated by compounds
407882, 118208 or 407882þ118208. Current
densities normalized to cell capacitance (pA/pF)
were calculated as the differences between
current values in the presence of CPT-cAMP/
IBMX minus current values after inhibition with
5mM CFTRinh-172.
C. Summary of mean CFTR current amplitudes
recorded at 60mV and normalized to cell
capacitance in cells treated for 24 h at 37˚C with
the indicated compounds or at 27˚C as a positive
control (meansþ SEM; n¼6–12); p¼0.05;
p¼0.008 for DMSO, p¼0.007 for 407882;
p¼0.003 for 130813, p¼0.00004 for
118208, p¼0.0005 for 407882þ118208,
p¼0.0007 for VX-809, p¼0.003 for Corr-4a,
p¼0.002 for 27˚C, versus the corresponding
vehicles (water or DMSO). Statistics: unpaired
Student’s t-test. NT, untreated cells.
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1490like in I efﬂux experiments. Low temperature treatment was
the most efﬁcient corrector, increasing current density to
near 40 pA/pF, which corresponded to a 90‐fold increase as
compared to untreated cells cultured at 37°C.
Incubation of cells with either Corr‐4A or VX‐809 increased
current density to15.8 and20.8 pA/pF respectively (3.5‐ and
4.2‐fold increase as compared with DMSO treatment alone).
Increases in current density comparable to that induced by the
two correctors Corr‐4A and VX‐809 were observed when cells
were treated by pocket 1‐binding compounds 118208 and
130813 or by pocket 2‐binding compounds 407882 and 73100,
ranging from 13.1 pA/pF (compound 130813) to 24.2 pA/pF
(compound 73100). Of note, the level of current density was not
more elevated when cells were treated by compound 407882
as compared with the other compounds, contrary to what was
observed during I ﬂux experiments (Fig 2B). However, in terms
of fold increase, current density was increased by near 40‐fold 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.by compound 407882 dissolved in water as compared with
untreated cells, whereas stimulation ranged from 3.5‐ to 6.5‐fold
for the other compounds dissolved in DMSO as compared with
vehicle alone. Twenty‐four‐hour pre‐treatment with 1mM of
118208 plus 1mM 407882 led to greater IDF508‐CFTR increase
than with the compounds alone but this increase did not reach
signiﬁcance as compared to compounds alone.
Treatment of WT‐CFTR‐expressing HeLa cells with
either 407882 or 118208 did not change DICFTR (data not
shown).
Correction of CFTR‐Cl conductance in human airway
epithelial cells
To test if the compounds behaving as correctors in HeLa cells
have the same properties in human airway epithelial cells we
performed two series of experiments. In the ﬁrst series, the
effects of the four molecules that were active in HeLa cells onEMBO Mol Med (2013) 5, 1484–1501
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serous cell line derived from a DF508 homozygous CF
patient expressing low amounts of endogenous DF508‐CFTR.
Compounds 407882 and 118208 induced signiﬁcant cAMP‐
dependent I efﬂux in these epithelial cells (Fig 5A; representa-
tive I efﬂux curve in cells treated for 2 hwith 407882 is shown in
Fig 5B). However, it must be noted that compounds 130813 and
73100 that modiﬁedDF508‐CFTR function in HeLa cells were not
active in this cell line.
In the second series of experiments, we investigated if the
treatment of polarized human bronchial primary epithelial cells
from CF patients (CF‐HBE) cultured in air–liquid conditions with
either 407882 or 118208 (1mM for 24 h) leads to functional
correction of DF508‐CFTR by short‐circuit current experimentsFigure 5. Iodide efﬂux in CF‐KM4 cells.
A. Effect of treatment with different compounds (73100, 37173, 118208,
407882) at 1mM for 2 h. The values represent the meanþ SEM of four
independent experiments; p¼0.02, p¼0.004. Statistics: One-way
Anova test followed by Bonferroni post hoc test.
B. Representative I efflux curves in cells treated for 2 h with 407882 in
response to co-treatment with 1mM Fsk and 30mM Gst as indicated by the
horizontal bar above each trace. NT, untreated cells.
EMBO Mol Med (2013) 5, 1484–1501 (Isc). Fig 6A shows that in our experimental conditions treatment
with 0.0002% DMSO led to almost no changes in Isc (upper
left panel). Treatment with either 407882 (lower left panel)
or 118208 (upper right panel) induced cAMP‐dependent
Cl current inhibited by CFTRinh172 by 3.9 1.2 and
4.4 1.8mA/cm2, n¼ 4 respectively, suggesting that the
observed current was carried by CFTR. Comparatively, in
non‐CF HBE cells (i.e. cells expressing WT‐CFTR), the increase
in cAMP‐dependent Cl current inhibited by CFTRinh172 was of
24.5 4.5mA (n¼ 4), indicating that correction was between 15
and 17% of CFTR current. In contrast to the results observed in
HeLa cells, in CF‐HBE the effect of both compounds
applied together was similar to the effect of individual treatments
(Fig 6A lower right panel and Fig 6B).
The treatment of HBE cells from two control subjects
with either 118208 or 407882 for 24 h did not change the
amplitude of cAMP‐dependent Cl current (2.8 and 6.7mA/cm2
before treatment vs. 2.5 and 6.9mA/cm2 after treatment).
Effect of 407882 treatment on nasal potential difference in
DF508 mice
We tested on a DF508/DF508 mouse model whether treatment
of nasal epithelium with one of the pocket 2 molecules leads
to correction of CFTR‐related Cl secretion by measuring
nasal potential difference changes (DVTE) (Sermet‐Gaudelus
et al, 2010). Among these molecules we chose 407882 because
of its water solubility, and used the following protocol: at
Day 0 VTE was measured; next week, at Days 7 and 8, 20ml
of 10mM 407882 was instilled into the nostrils of mice and
VTE was measured again at Day 10. We observed that
treatment of nasal epithelium with 407882 (according to
the protocol described in Materials and Methods Section)
resulted in CFTRinh172‐senstive hyperpolarization of DVTE
compatible with activation of the CFTR‐Cl channel
(4.8 1.8mV in four tested mice vs. 0.2 1.3mV in three
untreated mice; p¼ 0.006 using unpaired Student’s t‐test). It
must be noted that no inh172‐sensitive hyperpolarization of
DVTE was detected in control mice (Fig 7). By comparison,
DVTE in response to low Cl
 perfusion solution in WT mice
was 10.3 4.5mV, n¼ 8.
Inhibition of DF508‐CFTR‐keratin 8 interaction by compounds
407882 and 118208
We have shown in a previous study that disruption of interaction
between the intermediate ﬁlament protein keratin 8 and DF508‐
CFTR leads to functional correction of the mutated protein
(Colas et al, 2012). To test whether the compounds investigated
in the current study interrupt this interaction, we performed two
series of experiments: (i) a proximity ligation assay on HeLa cells
expressing DF508‐CFTR, and (ii) a surface plasmon resonance
assay (SPR). Fig 8A has been shown a dramatic decrease in
interaction, indicated by ﬂuorescent red spots, after treating cells
with 1mM of either 407882 or 118208, or of both compounds
(each dot reﬂects a proximity of <40 nm between a K8 and
DF508‐CFTR pair). Fig 8B is shown representative traces of K8
binding to DF508‐NBD1 in the presence and absence of 407882
and 407882þ 118208. Measurement of the maximum amounts2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1491
Figure 6. Rescue of DF508‐CFTR function by compounds 407882 and 118208 in primary airway epithelial cells.
A. Representative recordings showing response to 10mM Fsk/50mM IBMX and 20mM CFTRinh-172 in cells treated with DMSO (1/50,000), 118208, 407882 or
118208 plus 407882 at 1mM each for 24 h. Amiloride (100mM) was first added to the apical side to inhibit Naþ absorption occurring through Naþ channel
(ENaC), followed by addition of Fsk/IBMX (25 and 50mM).
B. Summary of data for transepithelial Cl current experiments. CFTR activity was evaluated bymeasuring the amplitude of the current inhibited by CFTRinh-172.
Values represent the meanþ SEM of four independent experiments; p¼3E08 for 118208, p¼8E09 for 407882, p¼1E05 for 118208þ407882;
Statistics: unpaired Student’s t-test.
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Figure 7. Effect of 407882 on nasal potential difference measurements in
DF508/DF508 mice. Representative traces of nasal potential difference
measurements in DF508/DF508 mice before and after treatment with 10mM
407882 administered in nostril twice within 48 h. 100mM amiloride-
containing solution was applied to inhibit ENaC current, followed by a low Cl
containing solution to unmask Cl secretion, and subsequently by 5mM
CFTRinh-172, and 100mM of non-CFTR anion transport inhibitor, DIDS.
A. Nasal potential (VTE) changes recorded 7 days before the first adminis-
tration of the compound (control).
B. VTE recorded 48 h after treatment of the same mouse with compound
407882.
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Section) after K8 addition indicates that either 407882 or
407882þ 118208 diminished by 15–20% the K8 association with
DF508‐NBD1. Evaluation of the initial association slope K8
(DRU/s) showed that the association rate diminishes by 10–22%
in the presence of 407882, and 40% in the presence of both
compounds (two independent experiments).
These data suggest that 407882 and 118208 perturbed K8 and
DF508‐CFTR interactions, what might imply an overlapping
between sites of action for K8 and both correctors.EMBO Mol Med (2013) 5, 1484–1501 Effect of compounds 407882 and 118208 onDF508‐NBD1 and
WT‐NBD1 structure
To test if the two compounds have a direct inﬂuence on NBD1
structure, we have applied hydrogen‐deuterium exchange
reaction coupled with mass spectrometry (HDex‐MS). According
to the results from MD simulations the DF508‐NBD1 structure
conformation used for virtual screening (a docking frame)
protocol was unobservable in the WT‐NBD1 trajectories
(Wieczorek & Zielenkiewicz, 2008). However, the analysis of
WT‐NBD1 trajectory only in the regions of two binding pockets
has shown, that congenial conformations of residues forming
pocket 2 in ‘the docking frame’ could be observed (RMSD
1.5Å, Supporting Information Fig S3), whereas conformation
of residues forming pocket 1 in the ‘docking frame’ was
unachievable for WT‐NBD1 during all MD simulation time
(Supporting Information Fig S3). This suggests, that at least
118208 compound should bind to DF508‐NBD1 domain but not
to the WT. To verify this in silico observation, HDex‐MS
experiments were performed with both WT and DF508‐NBD1
proteins.
The global patterns of relative deuterium uptake in the
experiments in the presence and absence of compounds after
10 s of reaction for both proteins were similar but with noticeable
changes (Supporting Information Fig S4). A careful analysis
(Kreyszig, 1993; Lazar & Schwartz, 1967) revealed that some
differences in HDex reaction rates (NBD1s in the presence of
compounds vs. NBD1s without compounds) were outside of
X s and therefore statistically signiﬁcant (Supporting Informa-
tion Figs S5 and S6). The average changes in deuterium uptake
after addition the 118208 molecule were 2.3% forWT‐NBD1 and
3.7% for DF508‐NBD1, whereas 407882 compound induced
similar changes in both cases, 5.3 and 5.4% for WT‐NBD1
and DF508‐NBD1 respectively, suggesting a slight global
destabilising effect of both compounds on DF508 and WT‐
NBD1 structures.
All peptic peptides with signiﬁcant changes in HDex rate for
both DF508 andWT domains after addition of tested compounds
have been mapped onto DF508‐NBD1 ‘docking frame’ structure
(Fig 9A and B).
For DF508‐NBD1 peptides for which HDex rate changes were
registered upon presence of 118208 compound, seven had either
diminished (ﬁve peptides) or not sufﬁciently increased (two
peptides; Supporting Information Table S3 and Supporting
Information Fig S5A and B). Four out of these seven peptides
cover the region from L526 to L558 and are partly overlapped
with pocket 1 (Fig 9A). More detailed analysis of deuterium
uptake in peptides from this region of NBD1 indicates that
their relative decrease in HDex rates is actually limited to the
smaller region N538 to L558 which is in pocket 1 (Supporting
Information Fig S6A and B).
Regarding 407882 molecule, among peptic peptides with
signiﬁcant changes in HDex rate detected for DF508‐NBD1, only
four had diminished and one had not sufﬁciently increased in
HDex to be comprised within range of X  s (Supporting
Information Table S3 and Supporting Information Fig S5C and
D,). Two out of those ﬁve identiﬁed peptides encompass the
residues participate in the region of pocket 2 (Fig 9B). For2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1493
Figure 8.
A. Effect of 407882 and 118208 on interaction between K8 and CFTR in DF508-CFTR-expressing HeLa cells. Proximity ligation assay (PLA) of K8 and DF508-CFTR
in transfected HeLa cells. Red dots correspond to K8/DF508-CFTR interaction (proximity <40 nm), and blue staining to nuclei (DAPI). Control: untreated cells.
Results are representative of at least three independent experiments.
B. SPR analysis of K8 binding to humanDF508-NBD1 (2900 RU¼2900 pgmm2) in the absence (green curve) and presence (red curve) of 180mM407882 and/or
(blue curve 407882 plus 118208 compounds). Insert: expanded curves of initial RU change showing the changes in initial slopes (dashed lines).
Research Article www.embomolmed.org
Discovery of Novel DF508‐CFTR Correctors
1494experiment with WT‐NBD1 in the presence of 407882 com-
pound, surprisingly we have identiﬁed 4 peptides covered the
region of pocket 2 with signiﬁcant diminished HDex rate:
N505‐G509, N505‐S511, A559‐D567 and A559‐L570 (Fig 9B,
Supporting Information Table S4 and Supporting Information
Fig S6C and D). Additionally, the peptide D579‐E583 exhibits
diminished HDex rates after incubations DF508‐NBD1 with either 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.of compounds as well as WT‐NBD1 with 407882 compound
(Supporting Information Tables S3 and S4). This effect is probably
not speciﬁc allosteric reaction of structural changes.
Altogether these results suggest the 118208 compound affects
region of pocket 1 only in DF508‐NBD1, whereas 407882 affects
region of pocket 2 in DF508 and WT‐NBD1, what in fact is
convergent with MD simulation results.EMBO Mol Med (2013) 5, 1484–1501
Figure 9. (Continued)
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Figure 9. Effect of compounds 118208 and 407882 on DF508 and WT‐NBD1 structures tested by HDex‐MS experiment. The coverage of DF508 and
WT-NBD1 sequences by peptic peptides has been shown on (upper panels). The peptides have also been mapped onto the DF508-NBD1 structure – ‘docking
frame’ (lower panels), and coincidences between localization of binding pockets for each molecule and peptides with diminished hydrogen-deuterium exchange
rate have been indicated by dashed lines. Sequence coverage by peptic peptides was 94.5% for DF508-NBD1 and 97.5%, for WT-NBD1.
A. 118208.
B. 407882.
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Norbert Odolczyk et al.Binding areas versus full CFTR model
Two binding areas for virtual screening protocols have
been selected according to the results from DF508‐NBD1
molecular dynamic simulation only (Wieczorek & Zielenkiewicz,
2008). Thus it was of interest to localized those binding
places onto the structural model of the full CFTR protein.
The DF508‐NBD1 docking frame has been superimposed
onto CFTR structural coordinates prepared by Mornon et al
(2008). As has been shown on Supporting Information Fig S7,
the binding region for 407882 and 73100 compounds (pocket 2)
is occupied by ICL4 loop of the TMD2. The binding area
for 118208 and 130813 (pocket 1) has been localized on
the deep interaction interface between NBD1 and NBD2, and
in the CFTR model is occupied by two loops from NBD2
domain.DISCUSSION
In this work we utilize virtual screening strategy together with
the results from molecular dynamic simulation (Wieczorek &
Zielenkiewicz, 2008) to discover very effective compounds,
that are able to overcome trafﬁcking defect of DF508‐CFTR
protein leading to correction of CFTR function in DF508/
DF508 CF human cells and mice. All four molecules represent
different chemical classes (Fig 1 and Supporting Information
Table S1), which are novel in the ﬁeld of DF508‐CFTR
pharmacology and might provide a novel mechanism of
action.
The efﬁcacy of the compounds was conﬁrmed using several
assays based on the measurement of CFTRinh‐172‐sensitive I

efﬂux, CFTRinh‐172 sensitive chloride current and DF508‐CFTR
processing in different cell types. The EC50 of the four described
correctors ranged between 0.8 and >100mM, the active
concentrations for all compounds being 1mM. This indicates
that the identiﬁedmolecules lie within the same correction range
as VX‐809, considered as the best corrector described to date
(currently being subjected to a clinical trial; http://clinical trials.
gov), and substantially more effective than VRT‐325 (Van
Goor et al, 2006) and RDR1 (Sampson et al, 2011). Notably, the
effect of 1mM 407882 on HeLa cells was as potent as 10mM of
VX‐809.
Additive and/or synergistic correction was observed in
DF508‐CFTR‐expressing HeLa cells treated with two com-
pounds, either 407882 plus 118208 or 73100 plus 407882,
reaching the correction amplitude observed in cells cultured at
27°C. In CF HBE primary cultured cells treated with 1mM of
407882, Cl transport reached 15% of non‐CF HBE cells. This
represents the same level of Cl transport correction as with
3mM VX‐809 in cultured HBE cells, as previously described
(Van Goor et al, 2011). Importantly, 407882 is effective in vivo
since it corrects CFTR function in DF508/DF508 mice. The fact
that correction by 407882 was observed in all tested cell types
is an important ﬁnding, while it has been reported that
correcting effect is cell type dependent (Pedemonte
et al, 2005b). We even anticipate that the cell background
effect of our correctors may be less signiﬁcant due to theirEMBO Mol Med (2013) 5, 1484–1501 potential binding to DF508‐CFTR surface rather than to
interaction with proteins engaged in degradation pathways,
which can be speciﬁc for each cell type.
The most promising molecule, 407882, contains two phenyl-
phosphinic acid moieties, which occupy pocket 2 (Fig 1B).
The highly polar hydroxyphosphoryl groups create interactions
with protein residues such as Lys564, Arg560 and Ser492,
whereas the two phenyl rings are bound to the more
hydrophobic portions of pocket 2. The second compound that
was also predicted to bind to pocket 2, 73100, is chemically
distinct from the ﬁrst one, as it comprises terephthalic acid
and ﬂuorene moieties. Nevertheless, both 407882 and 73100
share the same pharmacophore. The two carboxyl groups
from the tetrapthalic moiety of 73100 perfectly overlap with
the two hydroxyphosphoryl groups of 407882, thus creating
electrostatic interactions with the same protein residues
(Fig 1B), whereas the ﬂuorene moiety is positioned in the
hydrophobic cleft of pocket 2 formed by Phe494, Phe490,
Met469 and Met472. Among the compounds predicted to bind
to pocket 1, 118208 represents a hypoxanthine derivative
substituted with (3‐nitrophenyl)methylsulfanyl group in posi-
tion 2 of a purine‐like ring. The hypoxanthine part ﬁts perfectly
into the deep cavity on DF508‐NBD1 surface and may create
three H‐bonds with protein residues Ser495, Ser557 and Asp572
(Fig 1A). The phenyl ring is positioned in the neighbourhood
of Tyr577.
Compound 130813 consists of an acridine ring, which has
recently been identiﬁed by Sondo et al as a corrector of DF508‐
CFTR trafﬁcking (Sondo et al, 2011). Since these authors
suggested that 9‐aminoacridine acts as a proteostasis regulator,
our hypothesis in case of 130813 needs to be interpreted with
caution. Nevertheless, the structure of 130813 is much more
arborescent and the 9‐aminoacridine ring is substituted with a
chloride atom, a methoxyl group and a very bulky 3‐hydroxy[(4‐
methylpiperazin‐1‐yl)methyl]phenyl moiety. The binding mode
of 130813 to pocket 1 signiﬁcantly differs from that of 118208;
however, the phenyl ring occupies a similar position in both
cases.
The concept of drug binding sites on the mutated NBD1 has
already been evoked with regard to potentiators by Moran et al
(2005) and recently proved experimentaly by differential scaning
ﬂuorimetry for RDR1 corrector (Sampson et al, 2011). In our
studies we used HDex‐MS technique, to check whether our
computationally predicted molecules might in fact speciﬁcally
interact with DF508‐NBD1. Contrary to expectations, we
observed rather a slight global destabilization of NBD1 proteins
by 118208 and 407882 compound. However this destabilization
was prevented in regions overlapped with in silico predicted
pockets 1 and 2. This observation might suggest direct
interactions with DF508‐NBD1.
Interestingly, neighbourhood of binding region for 407882 has
been already indicated by Mornon as potential target for
pharmacological intervention by small molecule (Mornon
et al, 2008). According to the authors such compound should
form stabilize interaction between NBD1 and ICL4, which is
suspected to be altered in DF508‐CFTR and causes folding defect
(Mendoza et al, 2012; Rabeh et al, 2012). It also has been used for2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1497
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of DF508‐CFTR (Kalid et al, 2010) and were indicated as putative
binding place for VX‐809 (He et al, 2013). In both cases, in silico
studies were performed on full length CFTR structural model and
binding pockets consisting of NBD1 and ICL4 residues. In
contrast to previous studies the binding pocket for 407882 is fully
localized onto the NBD1 domain, and molecule perfectly
occupied place where ICL4 loop should reside (Supporting
Information Fig S7).
In the studies presented by Kalid et al, three putative cavities
on the full‐length CFTR structural model have been deﬁned as
independent receptors for VS (Kalid et al, 2010). The most
important difference between this study and ours was the
conceptual approach. Firstly, they tried to identify molecules
that would stabilize the protein by potentially affecting either the
folding yield or the surface stability. Thus, all putative binding
places were identiﬁed on the full CFTR protein and were
localized on inter‐domain interfaces like NBD1‐NBD2, NBD1‐
ICL4 and NBD1‐NBD2‐ICL1:2:4. Secondly, authors omitted an
exhaustive testing of dynamic behaviour of DF508‐CFTR, what
was a crucial aspect in our VS protocol. Especially in the case of
binding pocket 1, which was absent in the DF508‐NBD1 crystal
structure.
Among the most efﬁcient DF508‐CFTR correctors described to
date VX‐809, Corr‐4a and VRT‐325 are also suspected to directly
target the structure of mutated protein, however the putative site
of action for all of them remain unknown (He et al, 2013; Kim
et al, 2010; Wang et al, 2007), and for the last two some results
suggested even more general mechanism involved in protein
processing (Van Goor et al, 2011). Commonly accepted
mechanisms by which molecules induce protein trafﬁcking to
the plasma membrane is stabilization of the protein structure
and promotion of proper folding.
However for our study, we have to keep in mind that an
‘abnormal’ conformation was targeted, which might suggest a
different way of action. Thus we postulate the alternative
concept of correction mechanism for our molecules, which has
been built on previous results fromMD studies onWT‐NBD1 and
DF508‐NBD1 domains (Wieczorek & Zielenkiewicz, 2008). In
this context, we believe that we have identiﬁed molecules that
probably inhibit interactions between DF508‐CFTR and house-
keeping protein, rather than stabilize a mutated domain that is
very distinct from the native one. Moreover, our results rule out
the stabilization of NBD1 as a mechanism of action of new
correctors , thus HDex‐MS experiments have shown only slightly
stabilization of binding pockets regions, whereas over all
structure of DF508‐NBD1 is rather destabilized in presence of
our compounds. Previously, we have shown that disruption
of interaction between DF508‐CFTR and keratin 8 leads
to restoration functional DF508‐CFTR. We proposed site of
K8‐DF508‐CFTR interaction as novel therapeutic target for
DF508/DF508 CF patients (Colas et al, 2012). The results of
proximity DNA ligation and SPR experiments are in favour of
this hypothesis (Fig 8).
In conclusion, the chemical compounds identiﬁed by us as
correctors of DF508‐CFTR are very promising as potential
therapeutic agents. A correction level between 10% and 30% of 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.the WT‐CFTR activity has been estimated as the threshold
required to ameliorate the symptoms of CF (McKone et al, 2003;
Zhang et al, 2009). In our study, this correction threshold is
obtained even by treatment with a single molecule, something
that has been attainable with VX‐809 (Van Goor et al, 2011).
Notably, the fact that our most potent molecule, 407882, is
water‐soluble represents a favourable characteristic for drug
administration.MATERIALS AND METHODS
Study approval
All animal protocols used in the present study were approved by the
Institutional Animal Care and Use Committees of the INSERM.
Virtual screening
Detailed information about preparation of NCIDS database and
receptors using SYBYL 7.3 as well as full description of VS procedure
using Dock 6.1 (Moustakas et al, 2006) are provided in Supporting
Information Materials and Methods Section.
Reagents and antibodies, cell culture, immunoblot
experiments, transepithelial Cl current measurements and
hydrogen deuterium exchange MS
All reagents, antibodies, detailed information on cell culture,
transepithelial ion transport and hydrogen deuterium exchange
MS are provided in Supporting Information Materials and Methods
Section.
Iodide efﬂux experiments
CFTR chloride channel activity was assayed by measuring iodide (125I)
efﬂux from transfected HeLa cells as described previously (Marivingt‐
Mounir et al, 2004). Detailed information is provided in Supporting
Information Materials and Methods Section.
Whole cell patch clamp recordings
The technique for patch clamp recordings in the whole cell
conﬁguration has been described elsewhere (Hinzpeter et al, 2006;
Tanguy et al, 2008). Detailed information is provided in Supporting
Information Materials and Methods Section.
Nasal potential difference (NPD) measurements
The method for nasal potential measurement was adapted from the
technique developed for young children (Sermet‐Gaudelus et al, 2010).
Detailed information is provided in Supporting Information Materials
and Methods Section.
Proximity ligation assay
Cells were ﬁxed with cold acetone and analysed using the Duolink™ kit
(Eurogentec, Angers, France) according to manufacturer’s instructions.
Detailed information is provided in Supporting Information Materials
and Methods Section.
Surface plasmon resonance
Protein–ligand interactions were studied in real time using a SPR
Biacore 2000 system and CM5 sensor chips (GE Healthcare). NBD1 (WTEMBO Mol Med (2013) 5, 1484–1501
The paper explained
PROBLEM:
Cystic fibrosis (CF) is a fatal autosomal recessive genetic disorder
caused by mutations in the CFTR gene, which encodes CF
transmembrane conductance regulator (CFTR), a protein with
Cl channel functions. Deletion of Phe508 (DF508) in the first
nucleotide binding domain (NBD1) of CFTR is the most common
mutation associated with CF. The DF508-CFTR is recognized as
improperly folded and targeted for proteasomal degradation.
Thus, a significant decrease in functional CFTR expression occurs
at the apical plasma membrane that leads to abnormal Cl
transport across numerous epithelia and is responsible for a
severe form of CF.
RESULTS:
Here we apply a virtual screening strategy together with the
results frommolecular dynamics simulation to discover four very
effective compounds (correctors), that are able to overcome the
defect of DF508-CFTR and leading to correction of CFTR function
in various cell types including primary culture of human
bronchial CF cells and the nasal epithelium of homozygous
DF508-CFTR mice. Using different functional assays we
demonstrate that the newly identified compounds induce
functional expression of DF508-CFTR within the same correction
range as VX-809, considered as the best corrector described to
date (and currently being subjected to a clinical trial). We also
propose a newmechanism of action for the identified molecules,
possible based on the inhibition of theDF508-CFTR and keratin 8
interactions, as supported by proximity DNA ligation and surface
plasmon resonance experiments.
IMPACT:
These compounds are among the most potent correctors of the
DF508-CFTR trafficking defect known to date and appear very
promising as potential therapeutic agents.
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Norbert Odolczyk et al.and DF508) were covalently immobilized via primary amino groups on
the sensor chip surface, at 20°C, as described by Colas et al (2012).
Other details are in Supporting Information Materials and Methods
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